In this work, we found that IL-6 is an independent risk factor of POD onset, thus, making more robust the theory of inflammation as crucial substrate of the great majority of age-related pathologies (cancer, osteoarthritis, neurodegeneration including Alzheimer disease and dementia, type II diabetes among other), syndromes (frailty, depression disorders), and conditions, such as sarcopenia and obesity. This evidence concerns the gene IL6 and Down syndrome.